Invivyd’s (IVVD) Buy Rating Reiterated at HC Wainwright

Invivyd (NASDAQ:IVVD)‘s stock had its “buy” rating restated by investment analysts at HC Wainwright in a note issued to investors on Monday,Benzinga reports. They presently have a $10.00 target price on the stock.

Other equities analysts have also issued research reports about the company. D. Boral Capital reaffirmed a “buy” rating and set a $9.00 price target on shares of Invivyd in a research note on Monday. Morgan Stanley cut their target price on shares of Invivyd from $9.50 to $3.55 and set an “overweight” rating on the stock in a research report on Wednesday, November 20th. Finally, EF Hutton Acquisition Co. I upgraded shares of Invivyd to a “strong-buy” rating in a research report on Wednesday, October 30th. Four equities research analysts have rated the stock with a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat, the stock has an average rating of “Buy” and an average price target of $7.89.

Invivyd Stock Down 19.5 %

NASDAQ:IVVD traded down $0.35 during trading hours on Monday, hitting $1.43. 8,789,516 shares of the stock were exchanged, compared to its average volume of 24,734,166. The company has a market capitalization of $170.46 million, a P/E ratio of -0.73 and a beta of 0.61. The company’s 50 day moving average is $0.79 and its two-hundred day moving average is $0.86. Invivyd has a twelve month low of $0.35 and a twelve month high of $4.74.

Insider Buying and Selling at Invivyd

In related news, Director Terrance Mcguire sold 150,000 shares of the stock in a transaction that occurred on Monday, December 9th. The shares were sold at an average price of $0.61, for a total value of $91,500.00. Following the sale, the director now directly owns 4,538,079 shares in the company, valued at $2,768,228.19. This trade represents a 3.20 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at this link. Over the last quarter, insiders have sold 816,466 shares of company stock valued at $423,214. 17.90% of the stock is currently owned by company insiders.

Institutional Inflows and Outflows

A number of institutional investors have recently bought and sold shares of IVVD. Proficio Capital Partners LLC bought a new position in shares of Invivyd during the third quarter worth $27,000. Jane Street Group LLC raised its stake in Invivyd by 290.5% during the 4th quarter. Jane Street Group LLC now owns 117,432 shares of the company’s stock worth $52,000 after buying an additional 87,358 shares during the period. Barclays PLC grew its stake in Invivyd by 7.8% in the fourth quarter. Barclays PLC now owns 127,180 shares of the company’s stock valued at $56,000 after acquiring an additional 9,207 shares during the period. Renaissance Technologies LLC bought a new stake in shares of Invivyd in the fourth quarter worth about $74,000. Finally, JPMorgan Chase & Co. raised its position in shares of Invivyd by 644.1% during the fourth quarter. JPMorgan Chase & Co. now owns 256,900 shares of the company’s stock worth $114,000 after purchasing an additional 222,375 shares during the period. Institutional investors and hedge funds own 70.36% of the company’s stock.

About Invivyd

Invivyd, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of antibody-based solutions for infectious diseases in the United States. The company developed INVYMAB, a platform that combines viral surveillance and predictive modeling with advanced antibody engineering.